Atherosclerosis
Volume 213, Issue 1 , Pages 218-224 , November 2010

Effect of atorvastatin on kidney function in chronic kidney disease: A randomised double-blind placebo-controlled trial

  • Robert G. Fassett

      Affiliations

    • Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
    • Clifford Craig Medical Research Trust, Launceston, Tasmania, Australia
    • School of Human Life Sciences, University of Tasmania, Launceston, Tasmania, Australia
    • School of Human Movement Studies, The University of Queensland, Brisbane, Queensland, Australia
    • School of Medicine, The University of Queensland, Brisbane, Queensland, Australia
    • Corresponding Author InformationCorresponding author at: Renal Medicine, Level 9, Ned Hanlon Building, Royal Brisbane and Women's Hospital, Butterfield Street, Brisbane, Queensland 4029, Australia. Tel.: +61 419399571; fax: +61 736368572.
    • ,
  • Iain K. Robertson

      Affiliations

    • Clifford Craig Medical Research Trust, Launceston, Tasmania, Australia
    • School of Human Life Sciences, University of Tasmania, Launceston, Tasmania, Australia
    • ,
  • Madeleine J. Ball

      Affiliations

    • School of Human Life Sciences, University of Tasmania, Launceston, Tasmania, Australia
    • ,
  • Dominic P. Geraghty

      Affiliations

    • School of Human Life Sciences, University of Tasmania, Launceston, Tasmania, Australia
    • ,
  • Jeff S. Coombes

      Affiliations

    • School of Human Movement Studies, The University of Queensland, Brisbane, Queensland, Australia

Received 5 May 2010 ,Revised 25 July 2010 ,Accepted 28 July 2010.

References 

  1. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565–570
  2. Gheith OA, Sobh MA, Mohamed Kel S, et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron. 2002;91:612–619
  3. Agarwal R. Effects of statins on renal function. Mayo Clin Proc. 2007;82:1381–1390
  4. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260–269
  5. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–2016
  6. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336:645–651
  7. Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;CD007784
  8. Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009;53:741–750
  9. Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis. 2009;
  10. Johnson D. The CARI Guideline-Lipids. 2004;
  11. Fassett RG, Ball MJ, Robertson IK, Geraghty DP, Coombes JS. The Lipid Lowering and Onset of Renal Disease (LORD) trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol. 2008;9:4
  12. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766–772
  13. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349:1857–1863
  14. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in Nephropathy. Lancet. 1998;352:1252–1256
  15. Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998;31:954–961
  16. Martin JH, Fay MF, Ungerer JP. eGFR—use beyond the evidence. Med J Aust. 2009;190:197–199
  17. Douglas K, O’Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med. 2006;145:117–124
  18. Campese VM, Park J. HMG-CoA reductase inhibitors and renal function. Clin J Am Soc Nephrol. 2007;2:1100–1103
  19. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57:728–734
  20. McDonald S, Chang S, Excell L, ANZDATA Registry 2006 Report, In, 2007.
  21. Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2:1131–1139
  22. Lely AT, van der Kleij FG, Kistemaker TJ, et al. Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention. Clin J Am Soc Nephrol. 2008;3:54–60
  23. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl. 2003;S207–S210

☆ The study was registered with the http://www.anzctr.org.au number 012605000693628.

PII: S0021-9150(10)00598-8

doi: 10.1016/j.atherosclerosis.2010.07.053

Atherosclerosis
Volume 213, Issue 1 , Pages 218-224 , November 2010

Article Tools

* Image Usage & Resolution